These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Dopamine and migraine: a review of pharmacological, biochemical, neurophysiological, and therapeutic data. Mascia A; Afra J; Schoenen J Cephalalgia; 1998 May; 18(4):174-82. PubMed ID: 9642491 [TBL] [Abstract][Full Text] [Related]
5. Dopamine involvement in the migraine attack. Fanciullacci M; Alessandri M; Del Rosso A Funct Neurol; 2000; 15 Suppl 3():171-81. PubMed ID: 11200788 [TBL] [Abstract][Full Text] [Related]
6. Dopaminergic hypersensitivity in migraine: clinical and genetic evidence. Del Zompo M Funct Neurol; 2000; 15 Suppl 3():163-70. PubMed ID: 11200787 [TBL] [Abstract][Full Text] [Related]
7. Are dopaminergic neurons selectively vulnerable to Parkinson's disease? Agid Y; Ruberg M; Javoy-Agid F; Hirsch E; Raisman-Vozari R; Vyas S; Faucheux B; Michel P; Kastner A; Blanchard V Adv Neurol; 1993; 60():148-64. PubMed ID: 8420132 [No Abstract] [Full Text] [Related]
8. Biochemistry of Parkinson's disease 28 years later: a critical review. Agid Y; Cervera P; Hirsch E; Javoy-Agid F; Lehericy S; Raisman R; Ruberg M Mov Disord; 1989; 4 Suppl 1():S126-44. PubMed ID: 2566912 [No Abstract] [Full Text] [Related]
10. Dopamine hypersensitivity in migraine: role in apomorphine syncope. Del Zompo M; Lai M; Loi V; Pisano MR Headache; 1995 Apr; 35(4):222-4. PubMed ID: 7775179 [TBL] [Abstract][Full Text] [Related]
11. Possible mechanisms underlying the special vulnerability of dopaminergic neurons. Carlsson A; Fornstedt B Acta Neurol Scand Suppl; 1991; 136():16-8. PubMed ID: 1801531 [TBL] [Abstract][Full Text] [Related]
12. Effects of denervation and hyperinnervation on dopamine and serotonin systems in the rat neostriatum: implications for human Parkinson's disease. Reader TA; Dewar KM Neurochem Int; 1999 Jan; 34(1):1-21. PubMed ID: 10100192 [TBL] [Abstract][Full Text] [Related]
13. Impact of migraine on patients and their families: the Migraine And Zolmitriptan Evaluation (MAZE) survey--Phase III. MacGregor EA; Brandes J; Eikermann A; Giammarco R Curr Med Res Opin; 2004 Jul; 20(7):1143-50. PubMed ID: 15265259 [TBL] [Abstract][Full Text] [Related]
15. Embryonic dopamine cell implants as a treatment for the second phase of Parkinson's disease. Replacing failed nerve terminals. Freed CR; Breeze RE; Rosenberg NL; Schneck SA Adv Neurol; 1993; 60():721-8. PubMed ID: 8420217 [No Abstract] [Full Text] [Related]
16. Migraine is related to an increased risk of Parkinson's disease: A population-based, propensity score-matched, longitudinal follow-up study. Wang HI; Ho YC; Huang YP; Pan SL Cephalalgia; 2016 Dec; 36(14):1316-1323. PubMed ID: 26853806 [TBL] [Abstract][Full Text] [Related]
17. Opioid hypofunction in Parkinson's disease. Sandyk R; Gillman MA Med Hypotheses; 1985 Feb; 16(2):179-82. PubMed ID: 2581117 [TBL] [Abstract][Full Text] [Related]